Literature DB >> 7773734

Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke.

A Catto1, A Carter, H Ireland, T A Bayston, H Philippou, J Barrett, D A Lane, P J Grant.   

Abstract

To determine the prevalence of the factor V Leiden gene mutation in relation to the phenotypes of cerebral infarction and cerebral hemorrhage, we studied 386 randomly selected cases of acute stroke and 247 control subjects. Factor V genotype was determined by amplification of a 267-bp sequence of exon/intron 10 of the factor V gene. Levels of prothrombin fragment F(1 + 2), a marker of thrombin generation, were determined in both acute and convalescent stroke and related to factor V genotype. Prothrombin fragment F(1 + 2) was assessed by using an enzyme-linked immunosorbent assay. Sixteen stroke cases (4.1%) were identified as having the mutation compared with 14 (5.6%) control subjects. Prothrombin fragment F(1 + 2) levels were estimated in 191 cases and found to be elevated both acutely and after 3 months, but they were not related to factor V genotype. Prothrombin fragment F(1 + 2) is elevated in acute stroke and requires further evaluation in relation to cerebrovascular disease. These results suggest that the factor V Leiden gene mutation is not a risk factor for arterial thrombosis causing stroke.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7773734     DOI: 10.1161/01.atv.15.6.783

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  10 in total

1.  Prothrombin G20210A and factor V Leiden polymorphisms in stroke.

Authors:  Thierry Paluku They-They; Omar Battas; Ilham Slassi; Mohamed Abdou Rafai; Desire Tshala Katumbay; Sellama Nadifi
Journal:  J Mol Neurosci       Date:  2011-06-24       Impact factor: 3.444

Review 2.  Thrombophilia, polymorphisms, and vascular disease.

Authors:  T C Sykes; C Fegan; D Mosquera
Journal:  Mol Pathol       Date:  2000-12

3.  No Prognostic Importance of Resistance to Activated Protein C in Unstable Coronary Artery Disease Despite Signs of Thrombin Activation.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998       Impact factor: 2.300

Review 4.  Antithrombotic drug treatment of pediatric patients with ischemic stroke.

Authors:  Ulrike Nowak-Göttl; Ronald Sträeter; Guillaume Sébire; Fenella Kirkham
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

5.  Evaluation of the modifying effects of unfavourable genotypes on classical clinical risk factors for ischaemic stroke.

Authors:  Z Szolnoki; F Somogyvári; A Kondacs; M Szabó; L Fodor; J Bene; B Melegh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-12       Impact factor: 10.154

Review 6.  Clinical significance of gene-diagnosis for defects in coagulation factors and inhibitors.

Authors:  Herbert H Watzke
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

7.  Three periods of one and a half decade of ischemic stroke susceptibility gene research: lessons we have learned.

Authors:  Anita Maasz; Bela Melegh
Journal:  Genome Med       Date:  2010-09-13       Impact factor: 11.117

8.  The Siblings With Ischemic Stroke Study (SWISS) protocol.

Authors:  James F Meschia; Robert D Brown; Thomas G Brott; Felix E Chukwudelunzu; John Hardy; Stephen S Rich
Journal:  BMC Med Genet       Date:  2002-02-12       Impact factor: 2.103

9.  The Ischemic Stroke Genetics Study (ISGS) Protocol.

Authors:  James F Meschia; Thomas G Brott; Robert D Brown; Richard J P Crook; Michael Frankel; John Hardy; José G Merino; Stephen S Rich; Scott Silliman; Bradford Burke Worrall
Journal:  BMC Neurol       Date:  2003-07-08       Impact factor: 2.474

10.  The genetics of primary haemorrhagic stroke, subarachnoid haemorrhage and ruptured intracranial aneurysms in adults.

Authors:  George Peck; Liam Smeeth; John Whittaker; Juan Pablo Casas; Aroon Hingorani; Pankaj Sharma
Journal:  PLoS One       Date:  2008-11-14       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.